– Revenue increased 33% over prior year – – Several key milestones achieved – BOSTON and TEL AVIV, Israel, May 8, 2013 /PRNewswire/ — InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection stents, today announced financial results for the three month period…
InspireMD Sees 33% Revenue Increase Fuelled By MGuard™ Embolic Protection Stent
Revenue for the quarter to end March increased by 33% over prior year, reflecting the impact of several new marketing initiatives leveraging positive validation from the MASTER I trial of the Company’s MGuard™ Embolic Protection Stent (EPS™).